| 1 | upper | 9,817 |
| 2 | roux | 63 |
| 3 | mid-upper | 27 |
| 4 | nsaid-associated | 26 |
| 5 | 311-nm | 10 |
| 6 | less-impaired | 10 |
| 7 | 2-thumb-encircling | 9 |
| 8 | non-atypical | 9 |
| 9 | chedoke | 8 |
| 10 | d3p | 8 |
| 11 | deepwater | 8 |
| 12 | löe-silness | 8 |
| 13 | m3p | 8 |
| 14 | clo+ara-c | 7 |
| 15 | g2-4 | 7 |
| 16 | galactic | 7 |
| 17 | lymphedematous | 7 |
| 18 | more-impaired | 7 |
| 19 | folfiri+pb | 6 |
| 20 | midupper | 6 |
| 21 | myometric | 6 |
| 22 | non-shbg | 6 |
| 23 | tolerability-related | 6 |
| 24 | unexercised | 6 |
| 25 | advise-coitus | 5 |
| 26 | aspirin-exacerbated | 5 |
| 27 | dct/cddp | 5 |
| 28 | dyspeptic-type | 5 |
| 29 | endobarrier | 5 |
| 30 | hal-pdd | 5 |
| 31 | lymphoedematous | 5 |
| 32 | no-pdt | 5 |
| 33 | upper/lower | 5 |
| 34 | +mvc | 4 |
| 35 | asa-induced | 4 |
| 36 | capnometry-assisted | 4 |
| 37 | d/epi | 4 |
| 38 | dd/di | 4 |
| 39 | middle/lower | 4 |
| 40 | neck/upper | 4 |
| 41 | nonprosthetic | 4 |
| 42 | ramucirumab-pemetrexed-platinum | 4 |
| 43 | subglottal | 4 |
| 44 | bis-open | 3 |
| 45 | capecitabine-plus-lapatinib | 3 |
| 46 | cat+ | 3 |
| 47 | ch-t | 3 |
| 48 | fa/5-fu | 3 |
| 49 | ifg-striatum | 3 |
| 50 | infinite-time | 3 |
| 51 | ipilimumab-related | 3 |
| 52 | itn+irs | 3 |
| 53 | lower/upper | 3 |
| 54 | mlsg15-plus-mogamulizumab | 3 |
| 55 | more-affected | 3 |
| 56 | nonlower | 3 |
| 57 | nonrevascularizable | 3 |
| 58 | np220 | 3 |
| 59 | partner-a | 3 |
| 60 | partner-b | 3 |
| 61 | r-rt | 3 |
| 62 | rlq | 3 |
| 63 | rmfg-striatum | 3 |
| 64 | scp-care | 3 |
| 65 | sensor-on | 3 |
| 66 | shockley-queisser | 3 |
| 67 | trabectedin+pld | 3 |
| 68 | upper-lower | 3 |
| 69 | vc-aps | 3 |
| 70 | 'upper | 2 |
| 71 | 1,3-dioxane | 2 |
| 72 | 11,474 | 2 |
| 73 | 180/48 | 2 |
| 74 | 6/10/14 | 2 |
| 75 | 68-gy | 2 |
| 76 | 79.2-gy | 2 |
| 77 | ace+g-csf | 2 |
| 78 | adt+de | 2 |
| 79 | arylic | 2 |
| 80 | auto-positive | 2 |
| 81 | bartels | 2 |
| 82 | basis-set | 2 |
| 83 | bis-blinded | 2 |
| 84 | botox-treated | 2 |
| 85 | colds/upper | 2 |
| 86 | control-delayed | 2 |
| 87 | cp-alone | 2 |
| 88 | damage/adult | 2 |
| 89 | early/middle | 2 |
| 90 | exercise-injured | 2 |
| 91 | free-molecule | 2 |
| 92 | g3/g4 | 2 |
| 93 | genito | 2 |
| 94 | hwato | 2 |
| 95 | hypothalamico-hypophysial | 2 |
| 96 | ifl/bevacizumab | 2 |
| 97 | im-alone | 2 |
| 98 | influenza/acute | 2 |
| 99 | intervention-free | 2 |
| 100 | iso/dis | 2 |
| 101 | lamest | 2 |
| 102 | leafcutter | 2 |
| 103 | lobeline-elicited | 2 |
| 104 | lycra® | 2 |
| 105 | maximal-dosing | 2 |
| 106 | metformin-related | 2 |
| 107 | near-cathodal | 2 |
| 108 | no-occlusion | 2 |
| 109 | no-thalidomide | 2 |
| 110 | non-immobilized | 2 |
| 111 | non-lower | 2 |
| 112 | opisthosomal | 2 |
| 113 | poly-alanine | 2 |
| 114 | sertraline-only | 2 |
| 115 | sk-ntg | 2 |
| 116 | society-european | 2 |
| 117 | standard-of-care-only | 2 |
| 118 | striatum/anterior | 2 |
| 119 | temperature/pressure | 2 |
| 120 | tulle | 2 |
| 121 | upconverted | 2 |
| 122 | wte2 | 2 |
| 123 | 'pretend | 1 |
| 124 | -singly | 1 |
| 125 | 1-lod | 1 |
| 126 | 2-methyl-5-methoxyoxazoles | 1 |
| 127 | 2010.recurrent | 1 |
| 128 | 254-nm | 1 |
| 129 | 2xupper | 1 |
| 130 | 370-nm | 1 |
| 131 | 3×upper | 1 |
| 132 | 4×5-minutes | 1 |
| 133 | 5-florouracil/doxorubicin/cyclophosphamide | 1 |
| 134 | 6094 | 1 |
| 135 | abdominal/lower | 1 |
| 136 | active-agent | 1 |
| 137 | aflibercept-plus-folfiri | 1 |
| 138 | air-crystal | 1 |
| 139 | alcohol-rub | 1 |
| 140 | amygdala/temporal | 1 |
| 141 | aqueous-butanol | 1 |
| 142 | asthma/reactive | 1 |
| 143 | at-arm | 1 |
| 144 | atenolol-thiazide | 1 |
| 145 | atrophical | 1 |
| 146 | aureus-negative | 1 |
| 147 | bacteria/viral | 1 |
| 148 | baggy | 1 |
| 149 | bi-based | 1 |
| 150 | blinding/placebo-controlled | 1 |
| 151 | bortezomib-alone | 1 |
| 152 | bortezomib-plus-bevacizumab | 1 |
| 153 | c8/c13 | 1 |
| 154 | c9/c13 | 1 |
| 155 | carrageenan-evoked | 1 |
| 156 | catharreal | 1 |
| 157 | cd4/art | 1 |
| 158 | cdsmp-only | 1 |
| 159 | cement-simulated | 1 |
| 160 | children/study | 1 |
| 161 | chx-srv | 1 |
| 162 | citric-acid-mediated | 1 |
| 163 | clarithromycin-metronidazole | 1 |
| 164 | claudication/critical | 1 |
| 165 | clinically-detectable | 1 |
| 166 | coil-generated | 1 |
| 167 | cold/upper | 1 |
| 168 | collisionless | 1 |
| 169 | common/efferent | 1 |
| 170 | complete-basis-set | 1 |
| 171 | continue/stop | 1 |
| 172 | copd-connected | 1 |
| 173 | cox-1-related | 1 |
| 174 | craniodorsal | 1 |
| 175 | curd-improved | 1 |
| 176 | curzorn-ahlborn | 1 |
| 177 | d-sorbitol-oxidizing | 1 |
| 178 | dee-induced | 1 |
| 179 | desloratadine/montelukast | 1 |
| 180 | dihydrouridine | 1 |
| 181 | dis/pr | 1 |
| 182 | dna-weighted | 1 |
| 183 | dose-series | 1 |
| 184 | dy2o3 | 1 |
| 185 | e-only | 1 |
| 186 | ebl-induced | 1 |
| 187 | encephalitogen | 1 |
| 188 | enterococci-caused | 1 |
| 189 | extra-acute | 1 |
| 190 | extubation.non-invasive | 1 |
| 191 | fco1000 | 1 |
| 192 | fco500 | 1 |
| 193 | fda-accepted | 1 |
| 194 | fe-o-k-o | 1 |
| 195 | fibroelastotic | 1 |
| 196 | five-photon | 1 |
| 197 | four-pe | 1 |
| 198 | gad-positive | 1 |
| 199 | galantamine-treatment | 1 |
| 200 | globally-occurring | 1 |
| 201 | grass-cutting | 1 |
| 202 | h2-rich | 1 |
| 203 | haiflick | 1 |
| 204 | harmful/harmless | 1 |
| 205 | home-titration | 1 |
| 206 | hot-plate-induced | 1 |
| 207 | hp/high | 1 |
| 208 | iciq-lower | 1 |
| 209 | ifl/placebo | 1 |
| 210 | il-12/il-2 | 1 |
| 211 | immediate-intervention | 1 |
| 212 | induction/test-sequence | 1 |
| 213 | inf-γand | 1 |
| 214 | infinite-initial-temperature | 1 |
| 215 | infinite-volume | 1 |
| 216 | interest-rate | 1 |
| 217 | interframe | 1 |
| 218 | intermediate/special | 1 |
| 219 | intraoprative | 1 |
| 220 | ipsilesilesional | 1 |
| 221 | isolated/overall | 1 |
| 222 | ivermectin-resistant | 1 |
| 223 | kempen | 1 |
| 224 | kouk | 1 |
| 225 | l-ohp-administered | 1 |
| 226 | laparoscopy-induced | 1 |
| 227 | limb/uninvolved | 1 |
| 228 | locomotor-like | 1 |
| 229 | loss-oriented | 1 |
| 230 | lowest-dose-containing | 1 |
| 231 | lp/high | 1 |
| 232 | mage-a3+as15 | 1 |
| 233 | marginally-compensated | 1 |
| 234 | metalation-electrophile | 1 |
| 235 | metoclopramide/diphenhydramine | 1 |
| 236 | mf-like | 1 |
| 237 | mid-volar | 1 |
| 238 | mitoxatrone | 1 |
| 239 | montelukast/levocetirizine | 1 |
| 240 | mothra | 1 |
| 241 | myoblast-treatment | 1 |
| 242 | n-element | 1 |
| 243 | nanofluid-based | 1 |
| 244 | ne-driven | 1 |
| 245 | near-solubility | 1 |
| 246 | neuronic | 1 |
| 247 | nineupper | 1 |
| 248 | no-dt | 1 |
| 249 | no-home-titration | 1 |
| 250 | no-il-2 | 1 |
| 251 | no-study-treatment | 1 |
| 252 | no-us | 1 |
| 253 | non-adiabatically | 1 |
| 254 | non-breakaway | 1 |
| 255 | non-hemoglobin | 1 |
| 256 | non-lymphoedematous | 1 |
| 257 | non-marker-based | 1 |
| 258 | non-pressure | 1 |
| 259 | nonextreme | 1 |
| 260 | nonharvested | 1 |
| 261 | normo-fractionated | 1 |
| 262 | obesity/lower | 1 |
| 263 | obtund | 1 |
| 264 | oestroprogestinic | 1 |
| 265 | oro-pharyngo-laryngeal | 1 |
| 266 | ostreopsis-related | 1 |
| 267 | paired-reading | 1 |
| 268 | paleocene-eocene | 1 |
| 269 | panitumumab-containing | 1 |
| 270 | paper-administration | 1 |
| 271 | paroxistical | 1 |
| 272 | passive-strategy | 1 |
| 273 | pc/gefitinib | 1 |
| 274 | pegfilgrastin | 1 |
| 275 | peri-laryngeal | 1 |
| 276 | pfe-alone | 1 |
| 277 | pharmocogenetic | 1 |
| 278 | phosphatase-rhoa | 1 |
| 279 | photounstable | 1 |
| 280 | pimazzoni | 1 |
| 281 | placebo-clopidogrel | 1 |
| 282 | placebo-plus-folfiri | 1 |
| 283 | placenta-induced | 1 |
| 284 | pneumonia/acute | 1 |
| 285 | pneumonia/lower | 1 |
| 286 | porcelain- | 1 |
| 287 | post-furosemide | 1 |
| 288 | post-sperm | 1 |
| 289 | postswallow | 1 |
| 290 | pre-concentrating | 1 |
| 291 | pre-sam | 1 |
| 292 | precontemplation/loss | 1 |
| 293 | prepex/nonsurgical | 1 |
| 294 | proanthocyanidin-containing | 1 |
| 295 | protein’s | 1 |
| 296 | puva-alone | 1 |
| 297 | quaite-weighted | 1 |
| 298 | r/lpv+ral | 1 |
| 299 | radial-field | 1 |
| 300 | raltegravir-switch | 1 |
| 301 | responsefor | 1 |
| 302 | righteous | 1 |
| 303 | sag/alc | 1 |
| 304 | sag/pbo | 1 |
| 305 | scale-upper | 1 |
| 306 | sensor-off | 1 |
| 307 | servoventilator | 1 |
| 308 | sfgp | 1 |
| 309 | single-aperture | 1 |
| 310 | socs3-short | 1 |
| 311 | so₂-induced | 1 |
| 312 | stage-horn | 1 |
| 313 | standard-csa | 1 |
| 314 | standard/control | 1 |
| 315 | standard/high-risk | 1 |
| 316 | suberythematous | 1 |
| 317 | subjects/treatment | 1 |
| 318 | sublobar-caudate | 1 |
| 319 | sulfonylurea/insulin | 1 |
| 320 | surgery-or | 1 |
| 321 | taiwan-acute | 1 |
| 322 | tao-associated | 1 |
| 323 | tdf-switch | 1 |
| 324 | tdi/phbv | 1 |
| 325 | telephone-care | 1 |
| 326 | teriparatide-alone | 1 |
| 327 | thermocapillary-induced | 1 |
| 328 | thievery-pillager | 1 |
| 329 | tibilone | 1 |
| 330 | trapped-passing | 1 |
| 331 | trunk-lower | 1 |
| 332 | turp-related | 1 |
| 333 | two-pe | 1 |
| 334 | tψc | 1 |
| 335 | ultrastrong-coupling | 1 |
| 336 | unspecifical | 1 |
| 337 | venographically-proven | 1 |
| 338 | wall-to-fluid | 1 |
| 339 | yeniköy | 1 |
| 340 | zenithal | 1 |
| 341 | zero-positive | 1 |
| 342 | ≥5×upper | 1 |
| 1 | 'pretend | 1 |
| 2 | 'upper | 2 |
| 3 | +mvc | 4 |
| 4 | -singly | 1 |
| 5 | 1,3-dioxane | 2 |
| 6 | 1-lod | 1 |
| 7 | 11,474 | 2 |
| 8 | 180/48 | 2 |
| 9 | 2-methyl-5-methoxyoxazoles | 1 |
| 10 | 2-thumb-encircling | 9 |
| 11 | 2010.recurrent | 1 |
| 12 | 254-nm | 1 |
| 13 | 2xupper | 1 |
| 14 | 311-nm | 10 |
| 15 | 370-nm | 1 |
| 16 | 3×upper | 1 |
| 17 | 4×5-minutes | 1 |
| 18 | 5-florouracil/doxorubicin/cyclophosphamide | 1 |
| 19 | 6/10/14 | 2 |
| 20 | 6094 | 1 |
| 21 | 68-gy | 2 |
| 22 | 79.2-gy | 2 |
| 23 | abdominal/lower | 1 |
| 24 | ace+g-csf | 2 |
| 25 | active-agent | 1 |
| 26 | adt+de | 2 |
| 27 | advise-coitus | 5 |
| 28 | aflibercept-plus-folfiri | 1 |
| 29 | air-crystal | 1 |
| 30 | alcohol-rub | 1 |
| 31 | amygdala/temporal | 1 |
| 32 | aqueous-butanol | 1 |
| 33 | arylic | 2 |
| 34 | asa-induced | 4 |
| 35 | aspirin-exacerbated | 5 |
| 36 | asthma/reactive | 1 |
| 37 | at-arm | 1 |
| 38 | atenolol-thiazide | 1 |
| 39 | atrophical | 1 |
| 40 | aureus-negative | 1 |
| 41 | auto-positive | 2 |
| 42 | bacteria/viral | 1 |
| 43 | baggy | 1 |
| 44 | bartels | 2 |
| 45 | basis-set | 2 |
| 46 | bi-based | 1 |
| 47 | bis-blinded | 2 |
| 48 | bis-open | 3 |
| 49 | blinding/placebo-controlled | 1 |
| 50 | bortezomib-alone | 1 |
| 51 | bortezomib-plus-bevacizumab | 1 |
| 52 | botox-treated | 2 |
| 53 | c8/c13 | 1 |
| 54 | c9/c13 | 1 |
| 55 | capecitabine-plus-lapatinib | 3 |
| 56 | capnometry-assisted | 4 |
| 57 | carrageenan-evoked | 1 |
| 58 | cat+ | 3 |
| 59 | catharreal | 1 |
| 60 | cd4/art | 1 |
| 61 | cdsmp-only | 1 |
| 62 | cement-simulated | 1 |
| 63 | ch-t | 3 |
| 64 | chedoke | 8 |
| 65 | children/study | 1 |
| 66 | chx-srv | 1 |
| 67 | citric-acid-mediated | 1 |
| 68 | clarithromycin-metronidazole | 1 |
| 69 | claudication/critical | 1 |
| 70 | clinically-detectable | 1 |
| 71 | clo+ara-c | 7 |
| 72 | coil-generated | 1 |
| 73 | cold/upper | 1 |
| 74 | colds/upper | 2 |
| 75 | collisionless | 1 |
| 76 | common/efferent | 1 |
| 77 | complete-basis-set | 1 |
| 78 | continue/stop | 1 |
| 79 | control-delayed | 2 |
| 80 | copd-connected | 1 |
| 81 | cox-1-related | 1 |
| 82 | cp-alone | 2 |
| 83 | craniodorsal | 1 |
| 84 | curd-improved | 1 |
| 85 | curzorn-ahlborn | 1 |
| 86 | d-sorbitol-oxidizing | 1 |
| 87 | d/epi | 4 |
| 88 | d3p | 8 |
| 89 | damage/adult | 2 |
| 90 | dct/cddp | 5 |
| 91 | dd/di | 4 |
| 92 | dee-induced | 1 |
| 93 | deepwater | 8 |
| 94 | desloratadine/montelukast | 1 |
| 95 | dihydrouridine | 1 |
| 96 | dis/pr | 1 |
| 97 | dna-weighted | 1 |
| 98 | dose-series | 1 |
| 99 | dy2o3 | 1 |
| 100 | dyspeptic-type | 5 |
| 101 | e-only | 1 |
| 102 | early/middle | 2 |
| 103 | ebl-induced | 1 |
| 104 | encephalitogen | 1 |
| 105 | endobarrier | 5 |
| 106 | enterococci-caused | 1 |
| 107 | exercise-injured | 2 |
| 108 | extra-acute | 1 |
| 109 | extubation.non-invasive | 1 |
| 110 | fa/5-fu | 3 |
| 111 | fco1000 | 1 |
| 112 | fco500 | 1 |
| 113 | fda-accepted | 1 |
| 114 | fe-o-k-o | 1 |
| 115 | fibroelastotic | 1 |
| 116 | five-photon | 1 |
| 117 | folfiri+pb | 6 |
| 118 | four-pe | 1 |
| 119 | free-molecule | 2 |
| 120 | g2-4 | 7 |
| 121 | g3/g4 | 2 |
| 122 | gad-positive | 1 |
| 123 | galactic | 7 |
| 124 | galantamine-treatment | 1 |
| 125 | genito | 2 |
| 126 | globally-occurring | 1 |
| 127 | grass-cutting | 1 |
| 128 | h2-rich | 1 |
| 129 | haiflick | 1 |
| 130 | hal-pdd | 5 |
| 131 | harmful/harmless | 1 |
| 132 | home-titration | 1 |
| 133 | hot-plate-induced | 1 |
| 134 | hp/high | 1 |
| 135 | hwato | 2 |
| 136 | hypothalamico-hypophysial | 2 |
| 137 | iciq-lower | 1 |
| 138 | ifg-striatum | 3 |
| 139 | ifl/bevacizumab | 2 |
| 140 | ifl/placebo | 1 |
| 141 | il-12/il-2 | 1 |
| 142 | im-alone | 2 |
| 143 | immediate-intervention | 1 |
| 144 | induction/test-sequence | 1 |
| 145 | inf-γand | 1 |
| 146 | infinite-initial-temperature | 1 |
| 147 | infinite-time | 3 |
| 148 | infinite-volume | 1 |
| 149 | influenza/acute | 2 |
| 150 | interest-rate | 1 |
| 151 | interframe | 1 |
| 152 | intermediate/special | 1 |
| 153 | intervention-free | 2 |
| 154 | intraoprative | 1 |
| 155 | ipilimumab-related | 3 |
| 156 | ipsilesilesional | 1 |
| 157 | iso/dis | 2 |
| 158 | isolated/overall | 1 |
| 159 | itn+irs | 3 |
| 160 | ivermectin-resistant | 1 |
| 161 | kempen | 1 |
| 162 | kouk | 1 |
| 163 | l-ohp-administered | 1 |
| 164 | lamest | 2 |
| 165 | laparoscopy-induced | 1 |
| 166 | leafcutter | 2 |
| 167 | less-impaired | 10 |
| 168 | limb/uninvolved | 1 |
| 169 | lobeline-elicited | 2 |
| 170 | locomotor-like | 1 |
| 171 | loss-oriented | 1 |
| 172 | lower/upper | 3 |
| 173 | lowest-dose-containing | 1 |
| 174 | lp/high | 1 |
| 175 | lycra® | 2 |
| 176 | lymphedematous | 7 |
| 177 | lymphoedematous | 5 |
| 178 | löe-silness | 8 |
| 179 | m3p | 8 |
| 180 | mage-a3+as15 | 1 |
| 181 | marginally-compensated | 1 |
| 182 | maximal-dosing | 2 |
| 183 | metalation-electrophile | 1 |
| 184 | metformin-related | 2 |
| 185 | metoclopramide/diphenhydramine | 1 |
| 186 | mf-like | 1 |
| 187 | mid-upper | 27 |
| 188 | mid-volar | 1 |
| 189 | middle/lower | 4 |
| 190 | midupper | 6 |
| 191 | mitoxatrone | 1 |
| 192 | mlsg15-plus-mogamulizumab | 3 |
| 193 | montelukast/levocetirizine | 1 |
| 194 | more-affected | 3 |
| 195 | more-impaired | 7 |
| 196 | mothra | 1 |
| 197 | myoblast-treatment | 1 |
| 198 | myometric | 6 |
| 199 | n-element | 1 |
| 200 | nanofluid-based | 1 |
| 201 | ne-driven | 1 |
| 202 | near-cathodal | 2 |
| 203 | near-solubility | 1 |
| 204 | neck/upper | 4 |
| 205 | neuronic | 1 |
| 206 | nineupper | 1 |
| 207 | no-dt | 1 |
| 208 | no-home-titration | 1 |
| 209 | no-il-2 | 1 |
| 210 | no-occlusion | 2 |
| 211 | no-pdt | 5 |
| 212 | no-study-treatment | 1 |
| 213 | no-thalidomide | 2 |
| 214 | no-us | 1 |
| 215 | non-adiabatically | 1 |
| 216 | non-atypical | 9 |
| 217 | non-breakaway | 1 |
| 218 | non-hemoglobin | 1 |
| 219 | non-immobilized | 2 |
| 220 | non-lower | 2 |
| 221 | non-lymphoedematous | 1 |
| 222 | non-marker-based | 1 |
| 223 | non-pressure | 1 |
| 224 | non-shbg | 6 |
| 225 | nonextreme | 1 |
| 226 | nonharvested | 1 |
| 227 | nonlower | 3 |
| 228 | nonprosthetic | 4 |
| 229 | nonrevascularizable | 3 |
| 230 | normo-fractionated | 1 |
| 231 | np220 | 3 |
| 232 | nsaid-associated | 26 |
| 233 | obesity/lower | 1 |
| 234 | obtund | 1 |
| 235 | oestroprogestinic | 1 |
| 236 | opisthosomal | 2 |
| 237 | oro-pharyngo-laryngeal | 1 |
| 238 | ostreopsis-related | 1 |
| 239 | paired-reading | 1 |
| 240 | paleocene-eocene | 1 |
| 241 | panitumumab-containing | 1 |
| 242 | paper-administration | 1 |
| 243 | paroxistical | 1 |
| 244 | partner-a | 3 |
| 245 | partner-b | 3 |
| 246 | passive-strategy | 1 |
| 247 | pc/gefitinib | 1 |
| 248 | pegfilgrastin | 1 |
| 249 | peri-laryngeal | 1 |
| 250 | pfe-alone | 1 |
| 251 | pharmocogenetic | 1 |
| 252 | phosphatase-rhoa | 1 |
| 253 | photounstable | 1 |
| 254 | pimazzoni | 1 |
| 255 | placebo-clopidogrel | 1 |
| 256 | placebo-plus-folfiri | 1 |
| 257 | placenta-induced | 1 |
| 258 | pneumonia/acute | 1 |
| 259 | pneumonia/lower | 1 |
| 260 | poly-alanine | 2 |
| 261 | porcelain- | 1 |
| 262 | post-furosemide | 1 |
| 263 | post-sperm | 1 |
| 264 | postswallow | 1 |
| 265 | pre-concentrating | 1 |
| 266 | pre-sam | 1 |
| 267 | precontemplation/loss | 1 |
| 268 | prepex/nonsurgical | 1 |
| 269 | proanthocyanidin-containing | 1 |
| 270 | protein’s | 1 |
| 271 | puva-alone | 1 |
| 272 | quaite-weighted | 1 |
| 273 | r-rt | 3 |
| 274 | r/lpv+ral | 1 |
| 275 | radial-field | 1 |
| 276 | raltegravir-switch | 1 |
| 277 | ramucirumab-pemetrexed-platinum | 4 |
| 278 | responsefor | 1 |
| 279 | righteous | 1 |
| 280 | rlq | 3 |
| 281 | rmfg-striatum | 3 |
| 282 | roux | 63 |
| 283 | sag/alc | 1 |
| 284 | sag/pbo | 1 |
| 285 | scale-upper | 1 |
| 286 | scp-care | 3 |
| 287 | sensor-off | 1 |
| 288 | sensor-on | 3 |
| 289 | sertraline-only | 2 |
| 290 | servoventilator | 1 |
| 291 | sfgp | 1 |
| 292 | shockley-queisser | 3 |
| 293 | single-aperture | 1 |
| 294 | sk-ntg | 2 |
| 295 | society-european | 2 |
| 296 | socs3-short | 1 |
| 297 | so₂-induced | 1 |
| 298 | stage-horn | 1 |
| 299 | standard-csa | 1 |
| 300 | standard-of-care-only | 2 |
| 301 | standard/control | 1 |
| 302 | standard/high-risk | 1 |
| 303 | striatum/anterior | 2 |
| 304 | suberythematous | 1 |
| 305 | subglottal | 4 |
| 306 | subjects/treatment | 1 |
| 307 | sublobar-caudate | 1 |
| 308 | sulfonylurea/insulin | 1 |
| 309 | surgery-or | 1 |
| 310 | taiwan-acute | 1 |
| 311 | tao-associated | 1 |
| 312 | tdf-switch | 1 |
| 313 | tdi/phbv | 1 |
| 314 | telephone-care | 1 |
| 315 | temperature/pressure | 2 |
| 316 | teriparatide-alone | 1 |
| 317 | thermocapillary-induced | 1 |
| 318 | thievery-pillager | 1 |
| 319 | tibilone | 1 |
| 320 | tolerability-related | 6 |
| 321 | trabectedin+pld | 3 |
| 322 | trapped-passing | 1 |
| 323 | trunk-lower | 1 |
| 324 | tulle | 2 |
| 325 | turp-related | 1 |
| 326 | two-pe | 1 |
| 327 | tψc | 1 |
| 328 | ultrastrong-coupling | 1 |
| 329 | unexercised | 6 |
| 330 | unspecifical | 1 |
| 331 | upconverted | 2 |
| 332 | upper | 9,817 |
| 333 | upper-lower | 3 |
| 334 | upper/lower | 5 |
| 335 | vc-aps | 3 |
| 336 | venographically-proven | 1 |
| 337 | wall-to-fluid | 1 |
| 338 | wte2 | 2 |
| 339 | yeniköy | 1 |
| 340 | zenithal | 1 |
| 341 | zero-positive | 1 |
| 342 | ≥5×upper | 1 |
| 1 | cat+ | 3 |
| 2 | porcelain- | 1 |
| 3 | fco1000 | 1 |
| 4 | fco500 | 1 |
| 5 | np220 | 3 |
| 6 | no-il-2 | 1 |
| 7 | il-12/il-2 | 1 |
| 8 | wte2 | 2 |
| 9 | c8/c13 | 1 |
| 10 | c9/c13 | 1 |
| 11 | dy2o3 | 1 |
| 12 | g2-4 | 7 |
| 13 | 6/10/14 | 2 |
| 14 | 11,474 | 2 |
| 15 | 6094 | 1 |
| 16 | g3/g4 | 2 |
| 17 | mage-a3+as15 | 1 |
| 18 | 180/48 | 2 |
| 19 | partner-a | 3 |
| 20 | phosphatase-rhoa | 1 |
| 21 | mothra | 1 |
| 22 | standard-csa | 1 |
| 23 | partner-b | 3 |
| 24 | bortezomib-plus-bevacizumab | 1 |
| 25 | ifl/bevacizumab | 2 |
| 26 | mlsg15-plus-mogamulizumab | 3 |
| 27 | capecitabine-plus-lapatinib | 3 |
| 28 | pc/gefitinib | 1 |
| 29 | folfiri+pb | 6 |
| 30 | alcohol-rub | 1 |
| 31 | clo+ara-c | 7 |
| 32 | arylic | 2 |
| 33 | oestroprogestinic | 1 |
| 34 | neuronic | 1 |
| 35 | myometric | 6 |
| 36 | galactic | 7 |
| 37 | nonprosthetic | 4 |
| 38 | pharmocogenetic | 1 |
| 39 | fibroelastotic | 1 |
| 40 | sag/alc | 1 |
| 41 | +mvc | 4 |
| 42 | tψc | 1 |
| 43 | hal-pdd | 5 |
| 44 | asa-induced | 4 |
| 45 | placenta-induced | 1 |
| 46 | dee-induced | 1 |
| 47 | hot-plate-induced | 1 |
| 48 | ebl-induced | 1 |
| 49 | laparoscopy-induced | 1 |
| 50 | thermocapillary-induced | 1 |
| 51 | so₂-induced | 1 |
| 52 | bis-blinded | 2 |
| 53 | carrageenan-evoked | 1 |
| 54 | blinding/placebo-controlled | 1 |
| 55 | l-ohp-administered | 1 |
| 56 | more-impaired | 7 |
| 57 | less-impaired | 10 |
| 58 | exercise-injured | 2 |
| 59 | nanofluid-based | 1 |
| 60 | bi-based | 1 |
| 61 | non-marker-based | 1 |
| 62 | unexercised | 6 |
| 63 | enterococci-caused | 1 |
| 64 | aspirin-exacerbated | 5 |
| 65 | botox-treated | 2 |
| 66 | nsaid-associated | 26 |
| 67 | tao-associated | 1 |
| 68 | citric-acid-mediated | 1 |
| 69 | cox-1-related | 1 |
| 70 | ipilimumab-related | 3 |
| 71 | metformin-related | 2 |
| 72 | turp-related | 1 |
| 73 | ostreopsis-related | 1 |
| 74 | tolerability-related | 6 |
| 75 | cement-simulated | 1 |
| 76 | normo-fractionated | 1 |
| 77 | coil-generated | 1 |
| 78 | marginally-compensated | 1 |
| 79 | more-affected | 3 |
| 80 | copd-connected | 1 |
| 81 | dna-weighted | 1 |
| 82 | quaite-weighted | 1 |
| 83 | lobeline-elicited | 2 |
| 84 | loss-oriented | 1 |
| 85 | fda-accepted | 1 |
| 86 | upconverted | 2 |
| 87 | nonharvested | 1 |
| 88 | capnometry-assisted | 4 |
| 89 | limb/uninvolved | 1 |
| 90 | curd-improved | 1 |
| 91 | control-delayed | 2 |
| 92 | non-immobilized | 2 |
| 93 | wall-to-fluid | 1 |
| 94 | radial-field | 1 |
| 95 | trabectedin+pld | 3 |
| 96 | inf-γand | 1 |
| 97 | 'pretend | 1 |
| 98 | obtund | 1 |
| 99 | 1-lod | 1 |
| 100 | induction/test-sequence | 1 |
| 101 | adt+de | 2 |
| 102 | 5-florouracil/doxorubicin/cyclophosphamide | 1 |
| 103 | post-furosemide | 1 |
| 104 | no-thalidomide | 2 |
| 105 | atenolol-thiazide | 1 |
| 106 | intervention-free | 2 |
| 107 | mf-like | 1 |
| 108 | locomotor-like | 1 |
| 109 | chedoke | 8 |
| 110 | clinically-detectable | 1 |
| 111 | photounstable | 1 |
| 112 | nonrevascularizable | 3 |
| 113 | early/middle | 2 |
| 114 | metalation-electrophile | 1 |
| 115 | tulle | 2 |
| 116 | clarithromycin-metronidazole | 1 |
| 117 | free-molecule | 2 |
| 118 | interframe | 1 |
| 119 | nonextreme | 1 |
| 120 | infinite-time | 3 |
| 121 | infinite-volume | 1 |
| 122 | 1,3-dioxane | 2 |
| 123 | paleocene-eocene | 1 |
| 124 | dihydrouridine | 1 |
| 125 | metoclopramide/diphenhydramine | 1 |
| 126 | poly-alanine | 2 |
| 127 | montelukast/levocetirizine | 1 |
| 128 | puva-alone | 1 |
| 129 | bortezomib-alone | 1 |
| 130 | teriparatide-alone | 1 |
| 131 | pfe-alone | 1 |
| 132 | im-alone | 2 |
| 133 | cp-alone | 2 |
| 134 | tibilone | 1 |
| 135 | mitoxatrone | 1 |
| 136 | two-pe | 1 |
| 137 | four-pe | 1 |
| 138 | dyspeptic-type | 5 |
| 139 | telephone-care | 1 |
| 140 | scp-care | 3 |
| 141 | non-pressure | 1 |
| 142 | temperature/pressure | 2 |
| 143 | infinite-initial-temperature | 1 |
| 144 | single-aperture | 1 |
| 145 | sublobar-caudate | 1 |
| 146 | interest-rate | 1 |
| 147 | extra-acute | 1 |
| 148 | taiwan-acute | 1 |
| 149 | pneumonia/acute | 1 |
| 150 | influenza/acute | 2 |
| 151 | extubation.non-invasive | 1 |
| 152 | aureus-negative | 1 |
| 153 | intraoprative | 1 |
| 154 | asthma/reactive | 1 |
| 155 | gad-positive | 1 |
| 156 | zero-positive | 1 |
| 157 | auto-positive | 2 |
| 158 | sensor-off | 1 |
| 159 | ace+g-csf | 2 |
| 160 | non-shbg | 6 |
| 161 | paired-reading | 1 |
| 162 | 2-thumb-encircling | 9 |
| 163 | ultrastrong-coupling | 1 |
| 164 | panitumumab-containing | 1 |
| 165 | lowest-dose-containing | 1 |
| 166 | proanthocyanidin-containing | 1 |
| 167 | globally-occurring | 1 |
| 168 | maximal-dosing | 2 |
| 169 | trapped-passing | 1 |
| 170 | pre-concentrating | 1 |
| 171 | grass-cutting | 1 |
| 172 | d-sorbitol-oxidizing | 1 |
| 173 | sk-ntg | 2 |
| 174 | h2-rich | 1 |
| 175 | tdf-switch | 1 |
| 176 | raltegravir-switch | 1 |
| 177 | hp/high | 1 |
| 178 | lp/high | 1 |
| 179 | dd/di | 4 |
| 180 | pimazzoni | 1 |
| 181 | d/epi | 4 |
| 182 | placebo-plus-folfiri | 1 |
| 183 | aflibercept-plus-folfiri | 1 |
| 184 | haiflick | 1 |
| 185 | standard/high-risk | 1 |
| 186 | kouk | 1 |
| 187 | unspecifical | 1 |
| 188 | prepex/nonsurgical | 1 |
| 189 | atrophical | 1 |
| 190 | non-atypical | 9 |
| 191 | claudication/critical | 1 |
| 192 | paroxistical | 1 |
| 193 | near-cathodal | 2 |
| 194 | peri-laryngeal | 1 |
| 195 | oro-pharyngo-laryngeal | 1 |
| 196 | catharreal | 1 |
| 197 | zenithal | 1 |
| 198 | intermediate/special | 1 |
| 199 | hypothalamico-hypophysial | 2 |
| 200 | opisthosomal | 2 |
| 201 | ipsilesilesional | 1 |
| 202 | r/lpv+ral | 1 |
| 203 | bacteria/viral | 1 |
| 204 | amygdala/temporal | 1 |
| 205 | craniodorsal | 1 |
| 206 | air-crystal | 1 |
| 207 | subglottal | 4 |
| 208 | placebo-clopidogrel | 1 |
| 209 | isolated/overall | 1 |
| 210 | aqueous-butanol | 1 |
| 211 | standard/control | 1 |
| 212 | pre-sam | 1 |
| 213 | 370-nm | 1 |
| 214 | 311-nm | 10 |
| 215 | 254-nm | 1 |
| 216 | at-arm | 1 |
| 217 | post-sperm | 1 |
| 218 | ramucirumab-pemetrexed-platinum | 4 |
| 219 | ifg-striatum | 3 |
| 220 | rmfg-striatum | 3 |
| 221 | society-european | 2 |
| 222 | encephalitogen | 1 |
| 223 | kempen | 1 |
| 224 | bis-open | 3 |
| 225 | ne-driven | 1 |
| 226 | venographically-proven | 1 |
| 227 | non-hemoglobin | 1 |
| 228 | sulfonylurea/insulin | 1 |
| 229 | pegfilgrastin | 1 |
| 230 | sensor-on | 3 |
| 231 | no-occlusion | 2 |
| 232 | home-titration | 1 |
| 233 | no-home-titration | 1 |
| 234 | paper-administration | 1 |
| 235 | immediate-intervention | 1 |
| 236 | five-photon | 1 |
| 237 | curzorn-ahlborn | 1 |
| 238 | stage-horn | 1 |
| 239 | fe-o-k-o | 1 |
| 240 | ifl/placebo | 1 |
| 241 | sag/pbo | 1 |
| 242 | hwato | 2 |
| 243 | genito | 2 |
| 244 | d3p | 8 |
| 245 | m3p | 8 |
| 246 | dct/cddp | 5 |
| 247 | sfgp | 1 |
| 248 | continue/stop | 1 |
| 249 | rlq | 3 |
| 250 | mid-volar | 1 |
| 251 | thievery-pillager | 1 |
| 252 | endobarrier | 5 |
| 253 | upper | 9,817 |
| 254 | 'upper | 2 |
| 255 | mid-upper | 27 |
| 256 | scale-upper | 1 |
| 257 | cold/upper | 1 |
| 258 | neck/upper | 4 |
| 259 | lower/upper | 3 |
| 260 | colds/upper | 2 |
| 261 | midupper | 6 |
| 262 | nineupper | 1 |
| 263 | 2xupper | 1 |
| 264 | 3×upper | 1 |
| 265 | ≥5×upper | 1 |
| 266 | shockley-queisser | 3 |
| 267 | deepwater | 8 |
| 268 | leafcutter | 2 |
| 269 | trunk-lower | 1 |
| 270 | non-lower | 2 |
| 271 | iciq-lower | 1 |
| 272 | upper-lower | 3 |
| 273 | pneumonia/lower | 1 |
| 274 | middle/lower | 4 |
| 275 | abdominal/lower | 1 |
| 276 | upper/lower | 5 |
| 277 | obesity/lower | 1 |
| 278 | nonlower | 3 |
| 279 | surgery-or | 1 |
| 280 | responsefor | 1 |
| 281 | striatum/anterior | 2 |
| 282 | servoventilator | 1 |
| 283 | dis/pr | 1 |
| 284 | dose-series | 1 |
| 285 | 2-methyl-5-methoxyoxazoles | 1 |
| 286 | 4×5-minutes | 1 |
| 287 | iso/dis | 2 |
| 288 | bartels | 2 |
| 289 | vc-aps | 3 |
| 290 | itn+irs | 3 |
| 291 | harmful/harmless | 1 |
| 292 | collisionless | 1 |
| 293 | löe-silness | 8 |
| 294 | precontemplation/loss | 1 |
| 295 | no-us | 1 |
| 296 | righteous | 1 |
| 297 | lymphedematous | 7 |
| 298 | lymphoedematous | 5 |
| 299 | non-lymphoedematous | 1 |
| 300 | suberythematous | 1 |
| 301 | advise-coitus | 5 |
| 302 | protein’s | 1 |
| 303 | ch-t | 3 |
| 304 | no-dt | 1 |
| 305 | no-pdt | 5 |
| 306 | basis-set | 2 |
| 307 | complete-basis-set | 1 |
| 308 | damage/adult | 2 |
| 309 | ivermectin-resistant | 1 |
| 310 | active-agent | 1 |
| 311 | n-element | 1 |
| 312 | galantamine-treatment | 1 |
| 313 | myoblast-treatment | 1 |
| 314 | no-study-treatment | 1 |
| 315 | subjects/treatment | 1 |
| 316 | common/efferent | 1 |
| 317 | 2010.recurrent | 1 |
| 318 | r-rt | 3 |
| 319 | cd4/art | 1 |
| 320 | socs3-short | 1 |
| 321 | desloratadine/montelukast | 1 |
| 322 | lamest | 2 |
| 323 | fa/5-fu | 3 |
| 324 | tdi/phbv | 1 |
| 325 | chx-srv | 1 |
| 326 | postswallow | 1 |
| 327 | roux | 63 |
| 328 | non-breakaway | 1 |
| 329 | children/study | 1 |
| 330 | 79.2-gy | 2 |
| 331 | 68-gy | 2 |
| 332 | passive-strategy | 1 |
| 333 | baggy | 1 |
| 334 | -singly | 1 |
| 335 | non-adiabatically | 1 |
| 336 | e-only | 1 |
| 337 | sertraline-only | 2 |
| 338 | standard-of-care-only | 2 |
| 339 | cdsmp-only | 1 |
| 340 | near-solubility | 1 |
| 341 | yeniköy | 1 |
| 342 | lycra® | 2 |